Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Multiple myeloma and sarcopenia are inextricably linked. According to the research below, sarcopenia is a sort of sleeper side effect. I say this because:
The average MM patient is prone to sarcopenia. A diagnosis and treatment of MM speeds this average MM patient on the way to sarcopenia.
To be fair, we MM patients are focused on killing our MM. Or possible symptoms such as fatigue, nausea or peripheral neuropathy. The last thing on our minds is muscle loss.
Yet muscle loss can reduce our OS aks overall survival!
As is often the case, research advocates evidence-based non-conventional therapies such as:
Email me with at David.PeopleBeatingCancer@gmail.com with your questions about myeloma and sarcopenia.
Thank you,
“Sarcopenia is being consistently recognized as a condition not only associated with the presence of a malignancy but also induced by the oncologic therapies. Due to its negative impact on tolerance to chemotherapy and final outcome in both medical and surgical cancer patients, sarcopenia should be always considered and prevented, and, if recognized, should be appropriately treated.
A CT scan at the level of the third lumbar vertebra, using an appropriate software, is the more common and easily available way to diagnose sarcopenia. It is now acknowledged that mechanisms involved in iatrogenic sarcopenia are several and depending on the type of molecule included in the regimen of chemotherapy, different pharmacologic antidotes will be required in the future.
However, progression of the disease and the associated malnutrition per se are able to progressively erode the muscle mass and since sarcopenia is the hallmark of cachexia, the therapeutic approach to chemotherapy-induced sarcopenia parallels that of cachexia.
This approach mainly relies on those strategies which are able to increase the lean body mass and include the use of anabolic/anti-inflammatory agents, nutritional interventions, physical exercise and, even better, a combination of different therapies…”
“MM patients undergo rigorous treatment regimens including chemotherapy with steroids, autoHCT, as well as post-transplant continuous maintenance therapy. These interventions, though life prolonging, are likely to affect body composition. It is well known that steroids increase body fat as well as contribute to muscle atrophy, weakness, and fatigue.24
Recent literature identifies chemotherapy itself as a direct contributor to sarcopenia. Proposed mechanisms include:
Lifestyle interventions can modify sarcopenia.26–29 The goals of these interventions are to decrease fat mass, improve fat-associated dysregulation of metabolism and inflammation, increase muscle mass, and improve muscle strength and physical function.27
Studies show that low-calorie, high-protein diets in conjunction with physical activity with a focus on aerobic exercise resistance training are well-established interventions that have significantly improved muscle strength and composition and also decrease fat mass.26–28
Other novel therapies under investigation include pharmacologic therapies such as myostatin inhibitors and testosterone, among others.26, 28 Ongoing studies are needed to see if pharmacological therapies also have a role in the treatment of sarcopenia.26 Although various studies have identified ways to modify sarcopenia, interventions aimed at modifying sarcopenia in patients with MM have not been explored.27…”
myeloma and sarcopenia myeloma and sarcopenia